[go: up one dir, main page]

PL3549949T3 - Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania - Google Patents

Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania

Info

Publication number
PL3549949T3
PL3549949T3 PL19167276.5T PL19167276T PL3549949T3 PL 3549949 T3 PL3549949 T3 PL 3549949T3 PL 19167276 T PL19167276 T PL 19167276T PL 3549949 T3 PL3549949 T3 PL 3549949T3
Authority
PL
Poland
Prior art keywords
methods
clostridium difficile
difficile toxin
compositions relating
mutant clostridium
Prior art date
Application number
PL19167276.5T
Other languages
English (en)
Inventor
Maninder K. Sidhu
Annaliesa Sybil Anderson
Robert G. K. Donald
Kathrin Ute Jansen
Narender K. Kalyan
Terri L. MININNI
Justin Keith Moran
Mark E. Ruppen
Michael James Flint
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL3549949T3 publication Critical patent/PL3549949T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19167276.5T 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania PL3549949T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US201161478899P 2011-04-25 2011-04-25

Publications (1)

Publication Number Publication Date
PL3549949T3 true PL3549949T3 (pl) 2024-04-08

Family

ID=46085103

Family Applications (3)

Application Number Title Priority Date Filing Date
PL19151036.1T PL3505531T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostridium difficile i sposoby ich wytwarzania
PL19167276.5T PL3549949T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania
PL12720966T PL2699587T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną C. difficile i sposoby ich wytwarzania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19151036.1T PL3505531T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostridium difficile i sposoby ich wytwarzania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12720966T PL2699587T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną C. difficile i sposoby ich wytwarzania

Country Status (30)

Country Link
US (13) US8481692B2 (pl)
EP (4) EP2699587B1 (pl)
JP (8) JP5917682B2 (pl)
KR (1) KR101667837B1 (pl)
CN (3) CN111647059B (pl)
AR (1) AR086199A1 (pl)
AU (6) AU2012245904B2 (pl)
BR (2) BR112013027229B1 (pl)
CA (1) CA2832712C (pl)
CO (1) CO6801643A2 (pl)
DK (2) DK2699587T3 (pl)
ES (3) ES2742823T3 (pl)
FI (1) FI3549949T3 (pl)
HR (2) HRP20240042T1 (pl)
HU (2) HUE047085T2 (pl)
IL (8) IL270779B2 (pl)
MX (3) MX391236B (pl)
MY (2) MY182429A (pl)
NZ (1) NZ616035A (pl)
PE (2) PE20141029A1 (pl)
PH (1) PH12013502178B1 (pl)
PL (3) PL3505531T3 (pl)
PT (2) PT3549949T (pl)
RU (2) RU2592686C2 (pl)
SA (3) SA112330472B1 (pl)
SG (3) SG10201602668VA (pl)
SI (3) SI2699587T1 (pl)
TW (6) TWI686402B (pl)
WO (1) WO2012143902A1 (pl)
ZA (1) ZA201307818B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96768C2 (uk) * 2006-08-02 2011-12-12 Йоганес Гутенберг-Універсітет Майнц Лікарський засіб від lct-отруєнь
CA2745096C (en) * 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2916866B1 (de) * 2012-11-06 2018-04-04 Bayer Pharma Aktiengesellschaft Formulierung für bispecific t-cell-engangers (bites)
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
DK3174553T3 (en) * 2014-07-25 2018-07-23 Biosynth Srl GLYCOCOONJUGATE VACCINES INCLUDING BASIC UNITS OF A MOLECULE CONSTRUCTION THAT EXPRESSES MULTIPLE INTEGRATED EPITOPES FOR THE FORMULATION OF A WIDE-SPECTED VACCINE AGAINST INFECTIONS BASED ON BACTEROGEN
EP3256855B1 (en) * 2015-02-13 2020-10-07 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
CA3076961A1 (en) * 2017-09-28 2019-04-04 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
US20220160859A1 (en) * 2019-04-01 2022-05-26 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
US12343388B2 (en) 2019-05-10 2025-07-01 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile TcdB variants, vaccines and methods of use
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
CN115697330A (zh) * 2020-05-06 2023-02-03 阿尔伯特·爱因斯坦医学院 通过抑制肠道损伤性细菌毒素TcdA和TcdB预防来自艰难梭菌感染的组织损伤的活性剂
US20230218735A1 (en) 2020-06-19 2023-07-13 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
US20250177516A1 (en) 2022-03-14 2025-06-05 Pfizer Inc. Methods for producing an adjuvant
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
IL320955A (en) 2022-12-13 2025-07-01 Pfizer Immunogenic compounds and methods for generating an immune response against CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFCILE
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
JPH06509866A (ja) 1991-04-22 1994-11-02 マサチューセッツ　ヘルス　リサーチ　インスティチュート，インコーポレーテッド 呼吸系ウイルスに対する有効な抗体力価用の血漿試料をスクリーニングする方法
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
AU689772B2 (en) 1993-03-29 1998-04-09 Zoetis Llc Multicomponent clostridial vaccines using saponin adjuvants
AU702405B2 (en) 1994-09-06 1999-02-18 Immucell Corporation Therapeutic treatment of clostridium difficile associated diseases
DE69535530D1 (de) * 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
CA2226392A1 (en) 1995-07-07 1997-01-30 James S. Moncrief Intranasal vaccination against gastrointestinal disease
ATE195878T1 (de) 1995-07-07 2000-09-15 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
DE69635496T2 (de) 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
NZ333718A (en) 1996-07-12 2000-10-27 First Opinion Corp Computerized medical diagnostic system utilizing list-based processing
KR100382224B1 (ko) 1996-09-30 2003-04-26 엠브렉스, 인코포레이티드 백신 컨쥬게이트를 이용한 능동면역 생성방법
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
WO2000061762A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
CZ20023662A3 (cs) * 2000-05-04 2003-04-16 President And Fellows Of Harvard College Sloučeniny a způsoby léčení a prevence bakteriální infekce
ES2279869T3 (es) * 2001-06-20 2007-09-01 Ramot At Tel Aviv University Ltd. Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE602004010376T2 (de) * 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
AU2005206951B2 (en) 2004-01-16 2010-08-19 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
DK1766093T3 (da) * 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1833510A4 (en) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
US20070243199A1 (en) * 2006-03-30 2007-10-18 Embrex, Inc. Methods and compositions for vaccination of poultry
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
US20080206819A1 (en) 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2116997A4 (en) * 2007-03-02 2011-11-23 Panasonic Corp AUDIO-DECODING DEVICE AND AUDIO-DECODING METHOD
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
WO2009035707A1 (en) * 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
EP2288719A4 (en) 2008-05-15 2012-01-11 Univ Tufts METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION
WO2009156852A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
EP2329029B1 (en) 2008-09-24 2016-06-08 Sanofi Pasteur Biologics, LLC Methods and compositions for increasing toxin production
EP2346523A4 (en) 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
JP2012510497A (ja) 2008-12-03 2012-05-10 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ワクチンの生産方法
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
US8420352B2 (en) * 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
EP2519257A4 (en) * 2009-12-02 2014-10-15 Univ Tufts ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
BR112012024898A2 (pt) 2010-03-30 2015-10-06 Pfenex Inc expressão de nível elevado de proteínas recombinantes de toxinas
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
EP3167899B1 (en) * 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012078313A2 (en) * 2010-11-12 2012-06-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
EP3564378B1 (en) 2011-05-27 2023-11-01 GlaxoSmithKline Biologicals SA Immunogenic composition
US9770500B2 (en) * 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR112015004629A2 (pt) 2012-09-19 2017-11-21 Novartis Ag polipeptídeos de clostridium difficile como vacinas
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP2016501877A (ja) 2012-11-28 2016-01-21 シーエヌジェー ホールディングス，インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
AU2013354186A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
US20160045586A1 (en) 2013-03-15 2016-02-18 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
EP2981611A4 (en) 2013-04-02 2016-11-16 Stc Unm ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US20160250283A1 (en) 2013-10-23 2016-09-01 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1259103A1 (zh) 2015-11-17 2019-11-22 Pfizer Inc. 用於在细菌细胞培养物中生产多糖的培养基和发酵方法
MA44252A (fr) 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
AU2018236352B2 (en) 2017-03-15 2024-04-04 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
CA3076961A1 (en) 2017-09-28 2019-04-04 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
CN111647059A (zh) 2020-09-11
US20190202873A1 (en) 2019-07-04
US8900597B2 (en) 2014-12-02
JP6097853B2 (ja) 2017-03-15
US20230391835A1 (en) 2023-12-07
ES2742823T3 (es) 2020-02-17
KR101667837B1 (ko) 2016-10-20
MX347521B (es) 2017-04-27
FI3549949T3 (fi) 2024-01-30
MY168205A (en) 2018-10-15
SG10201911993UA (en) 2020-02-27
IL245047A0 (en) 2016-05-31
IL270779B2 (en) 2024-09-01
PE20181334A1 (es) 2018-08-21
TWI701257B (zh) 2020-08-11
JP2018052938A (ja) 2018-04-05
JP2021130692A (ja) 2021-09-09
PE20141029A1 (es) 2014-09-04
JP2022126822A (ja) 2022-08-30
IL254418A0 (en) 2017-11-30
HUE065594T2 (hu) 2024-06-28
US20130330371A1 (en) 2013-12-12
SG194132A1 (en) 2013-11-29
DK2699587T3 (da) 2019-08-05
US10597428B2 (en) 2020-03-24
JP7097478B2 (ja) 2022-07-07
CA2832712C (en) 2018-08-28
US9187536B1 (en) 2015-11-17
PH12013502178A1 (en) 2014-01-13
TW201302780A (zh) 2013-01-16
AU2018201296A1 (en) 2018-03-15
MY182429A (en) 2021-01-25
AU2019246878B2 (en) 2020-09-10
BR122019017005B1 (pt) 2022-03-29
PT2699587T (pt) 2019-09-05
RU2015154443A3 (pl) 2019-05-22
TW201932481A (zh) 2019-08-16
EP3549949B1 (en) 2023-11-29
PT3549949T (pt) 2024-02-02
IL265510A (en) 2019-05-30
SI2699587T1 (sl) 2019-08-30
TW202041525A (zh) 2020-11-16
USRE48863E1 (en) 2021-12-28
IL270779A (en) 2020-01-30
AU2012245904A1 (en) 2013-10-17
US8481692B2 (en) 2013-07-09
EP3505531B1 (en) 2023-11-15
ZA201307818B (en) 2014-06-25
USRE46376E1 (en) 2017-04-25
US20120269841A1 (en) 2012-10-25
BR112013027229A2 (pt) 2016-11-29
CN103619871B (zh) 2016-12-14
MX391236B (es) 2025-03-21
TWI804717B (zh) 2023-06-11
JP6735784B2 (ja) 2020-08-05
CN107022532A (zh) 2017-08-08
US20150307563A1 (en) 2015-10-29
CN103619871A (zh) 2014-03-05
USRE48862E1 (en) 2021-12-28
PL2699587T3 (pl) 2019-12-31
US9745354B2 (en) 2017-08-29
PH12013502178B1 (en) 2018-11-09
JP6321239B2 (ja) 2018-05-09
CN111647059B (zh) 2023-11-28
CA2832712A1 (en) 2012-10-26
MX385834B (es) 2025-03-18
SA115360697B1 (ar) 2016-04-05
US20150125927A1 (en) 2015-05-07
JP5917682B2 (ja) 2016-05-18
EP2699587A1 (en) 2014-02-26
ES2969952T3 (es) 2024-05-23
IL273231A (en) 2020-04-30
IL255345A0 (en) 2017-12-31
EP3549949A1 (en) 2019-10-09
JP2019052149A (ja) 2019-04-04
US20170313749A1 (en) 2017-11-02
BR112013027229B1 (pt) 2020-10-27
CN107022532B (zh) 2021-05-04
AU2020230248A1 (en) 2020-10-01
AR086199A1 (es) 2013-11-27
AU2017261465B2 (en) 2018-10-04
HUE047085T2 (hu) 2020-04-28
IL228944A (en) 2017-11-30
USRE46518E1 (en) 2017-08-22
TWI671313B (zh) 2019-09-11
PL3505531T3 (pl) 2024-03-11
RU2754446C2 (ru) 2021-09-02
EP4365196A3 (en) 2024-08-07
JP2017125030A (ja) 2017-07-20
RU2592686C2 (ru) 2016-07-27
NZ616035A (en) 2016-03-31
TW201932480A (zh) 2019-08-16
MX2013012344A (es) 2013-11-20
US11535652B2 (en) 2022-12-27
EP4365196A2 (en) 2024-05-08
IL254440B (en) 2019-12-31
IL255345B (en) 2021-05-31
AU2017261465A1 (en) 2017-11-30
EP2699587B1 (en) 2019-07-03
IL273231B (en) 2021-08-31
EP3505531A1 (en) 2019-07-03
JP2016117745A (ja) 2016-06-30
JP2018135345A (ja) 2018-08-30
US20130244307A1 (en) 2013-09-19
AU2012245904B2 (en) 2016-04-21
TW202320843A (zh) 2023-06-01
AU2020230248B2 (en) 2022-12-01
WO2012143902A1 (en) 2012-10-26
AU2016202903A1 (en) 2016-05-26
SA115360698B1 (ar) 2016-04-27
TWI650329B (zh) 2019-02-11
IL228944A0 (en) 2013-12-31
SI3505531T1 (sl) 2024-02-29
SG10201602668VA (en) 2016-05-30
TWI815599B (zh) 2023-09-11
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
IL265510B (en) 2021-05-31
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
CO6801643A2 (es) 2013-11-29
DK3549949T3 (da) 2023-12-18
KR20130140206A (ko) 2013-12-23
RU2013145170A (ru) 2015-06-27
AU2016202903B2 (en) 2017-11-30
HRP20240042T1 (hr) 2024-03-29
US10774117B2 (en) 2020-09-15
JP2014514318A (ja) 2014-06-19
HRP20231631T1 (hr) 2024-03-15
RU2015154443A (ru) 2019-01-17
AU2019246878A1 (en) 2019-10-31
SA112330472B1 (ar) 2015-11-02
TW201806967A (zh) 2018-03-01
DK3549949T5 (da) 2024-09-02
IL254418B (en) 2019-12-31
US20200095290A1 (en) 2020-03-26
ES2968629T3 (es) 2024-05-13
JP6892425B2 (ja) 2021-06-23
US8557548B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
IL273231B (en) Clostridium difficile toxin-related preparations and methods
IL284582A (en) Compositions and methods related to mutant Clostridium difficile toxin
SG10201602218VA (en) Novel fuel compositions and methods for making same
IL228607A0 (en) A preparation of lyophilized botulinum toxins
EP2668281A4 (en) COMPOSITIONS AND METHODS OF SUCCINATE MANUFACTURE
PL2731963T3 (pl) Kompozycje i sposoby do immunomodulacji
ZA201308892B (en) Compositions and methods
PL2841593T3 (pl) Dehydrogenaza i toksyna clostridium difficile jako biomarker
HUE050699T2 (hu) Készítmények és eljárások Spirocheták tenyésztésére
PL2729139T3 (pl) Produkt zmniejszający kaszel
GB201116340D0 (en) Compositions and methods